Celgene’s aggressive pricing and anti‑generic tactics for Thalidomide (Thalomid) and Revlimid

Celgene’s aggressive pricing and anti‑generic tactics for Thalidomide (Thalomid) and Revlimid The passage outlines concrete actions by Celgene executives—including references to specific individuals (Mr. Hugin) and internal strategy meetings—regarding illegal marketing, price hikes, and efforts to block generic competition. These details provide actionable leads (names, drug names, dates, pricing figures) that merit further investigation into possible antitrust violations and financial misconduct, though the excerpt lacks direct evidence of illegal conduct by government officials. Key insights: Celgene executives repeatedly cited Thalomid and Revlimid as the "key to the financial future" at an investor conference in 2004.; The company settled a lawsuit in 2017 related to protracted litigation over these drugs.; Pricing for a month’s supply of Thalidomide rose from $6,000 to $16,000 after the introduction of Revlimid.